Lamorna Brown-Swigart

Nov 6, 2024 | cell.com | Michael Campbell |Denise Wolf |Christina Yau |Lamorna Brown-Swigart |Isela R. Gallagher |Zelos Zhu | +20 more

ResultsA total of 69 HER2− patients (40 HR+HER2− and 29 TN) were randomized to receive 4 cycles of pembrolizumab in combination with weekly paclitaxel followed by anthracycline chemotherapy (Pembro+T → AC). In addition, there were 181 HER2− patients (96 HR+HER2− and 85 TN) randomized to the standard neoadjuvant chemotherapy control group (T → AC). We utilized three assay platforms to characterize the tumor immune microenvironment in these patients (Figure 1).

Sep 14, 2024 | nature.com | Katia Khoury |Hope Rugo |Rita Nanda |Alexandra Zimmer |Judy Boughey |Christos Vaklavas | +11 more

AbstractAmong the goals of patient-centric care are the advancement of effective personalized treatment, while minimizing toxicity. The phase 2 I-SPY2.2 trial uses a neoadjuvant sequential therapy approach in breast cancer to further these goals, testing promising new agents while optimizing individual outcomes. Here we tested datopotamab–deruxtecan (Dato-DXd) in the I-SPY2.2 trial for patients with high-risk stage 2/3 breast cancer.

Sep 13, 2024 | nature.com | Rita Nanda |Hope Rugo |Judy Boughey |Kevin Kalinsky |Christos Vaklavas |Claudine Isaacs | +8 more

AbstractSequential adaptive trial designs can help accomplish the goals of personalized medicine, optimizing outcomes and avoiding unnecessary toxicity.